Meridian Bioscience Announces Licensing Agreement With Cincinnati Children's Research Foundation
CINCINNATI--(BUSINESS WIRE)--May 26, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has entered into a license agreement with Cincinnati Children's Research Foundation for technologies related to the detection of norovirus, the primary cause of "stomach flu". This agreement, which is comprised of both exclusive and co-exclusive provisions, encompasses products for the clinical diagnosis of noroviruses and other products arising from the technology.
Noroviruses are a group of RNA viruses that are responsible for acute gastroenteritis in humans. These viruses are highly contagious and are most often transmitted through food that has been contaminated by infected workers and via person-to-person contact. The Centers for Disease Control estimates that 23 million cases of norovirus-associated gastroenteritis occur each year. Reported outbreaks have been traced to restaurant and catered meals, nursing homes, schools and cruise ships.
John A. Kraeutler, President and Chief Operating Officer, stated, "Ever since the cruise ship outbreaks in 2003, severe gastroenteritis incidents caused by norovirus have been reported with increasing frequency in the media. Due to the highly contagious nature of these viruses, the development of a rapid test that will enable early diagnosis of infected persons is paramount. Meridian is currently developing test methods for the identification of norovirus. This collaborative agreement with Cincinnati Children's Hospital Medical Center will enhance and accelerate the commercialization of Meridian's products. We believe this agreement is indicative of Ohio's emerging life science capabilities."
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections. All Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company's shares are traded through Nasdaq's National Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700
SOURCE: Meridian Bioscience, Inc.